OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+49.06%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$459M
AUM Growth
+$459M
(+22%)
Cap. Flow
-$115M
Cap. Flow
% of AUM
-25.1%
Top 10 Holdings %
Top 10 Hldgs %
57.01%
Holding
59
New
13
Increased
16
Reduced
16
Closed
7
Top Buys
| 1 |
Lyell Immunopharma
LYEL
|
$7.48M |
| 2 |
Compass Therapeutics
CMPX
|
$6.28M |
| 3 |
Ocular Therapeutix
OCUL
|
$5.31M |
| 4 |
Applied Therapeutics
APLT
|
$4.61M |
| 5 |
Intellia Therapeutics
NTLA
|
$4.29M |
Top Sells
| 1 |
Jasper Therapeutics
JSPR
|
$104M |
| 2 |
SLRN
ACELYRIN
SLRN
|
$17.3M |
| 3 |
IDEAYA Biosciences
IDYA
|
$11.1M |
| 4 |
Biohaven
BHVN
|
$8.56M |
| 5 |
Arcutis Biotherapeutics
ARQT
|
$6.33M |
Sector Composition
| 1 | Healthcare | 99.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ocular Therapeutix
OCUL
$2.12B
| $60.5M | 13.19% | 6,653,138 +583,138 | +10% | +$5.31M |
|
2
Harrow
HROW
$1.44B
| $51.9M | 11.3% | 3,920,600 +100,600 | +3% | +$1.33M |
|
3
TG Therapeutics
TGTX
$4.65B
| $34.7M | 7.56% | 2,280,000 +65,000 | +3% | +$989K |
|
4
Keros Therapeutics
KROS
$618M
| $24.3M | 5.3% | 367,500 +10,000 | +3% | +$662K |
|
5
Rhythm Pharmaceuticals
RYTM
$6.85B
| $22.3M | 4.86% | 515,000 -95,000 | -16% | -$4.12M |
|
6
Catalyst Pharmaceutical
CPRX
$2.52B
| $16M | 3.49% | 1,004,355 -252,845 | -20% | -$4.03M |
|
7
Arvinas
ARVN
$568M
| $13.6M | 2.97% | 330,000 +66,300 | +25% | +$2.74M |
|
8
Iovance Biotherapeutics
IOVA
$807M
| $13.3M | 2.9% | 897,000 | – | – |
|
|
9
Jasper Therapeutics
JSPR
$45.5M
| $12.8M | 2.79% | 435,573 -3,549,767 | -89% | -$104M |
|
10
Edgewise Therapeutics
EWTX
$1.51B
| $12.1M | 2.64% | 665,000 -34,000 | -5% | -$620K |
|
|
11
Applied Therapeutics
APLT
$71M
| $12M | 2.62% | 1,770,000 +677,500 | +62% | +$4.61M |
|
12
4D Molecular Therapeutics
FDMT
$288M
| $11M | 2.39% | 344,123 +35,623 | +12% | +$1.13M |
|
13
Codexis
CDXS
$246M
| $10.9M | 2.37% | 3,120,000 +74,475 | +2% | +$260K |
|
14
Protara Therapeutics
TARA
$120M
| $10.8M | 2.35% | 2,692,594 | – | – |
|
|
SLRN
15
DELISTED
ACELYRIN
SLRN
| $10.7M | 2.32% | 1,580,000 -2,566,138 | -62% | -$17.3M |
|
16
Crinetics Pharmaceuticals
CRNX
$2.92B
| $9.83M | 2.14% | 210,000 -97,500 | -32% | -$4.56M |
|
17
Eton Pharmaceutcials
ETON
$464M
| $9.17M | 2% | 2,445,781 -84,106 | -3% | -$315K |
|
18
Trevi Therapeutics
TRVI
$883M
| $9.13M | 1.99% | 2,645,000 +110,000 | +4% | +$380K |
|
|
19
Lyell Immunopharma
LYEL
$213M
| $7.48M | 1.63% | +3,355,000 | New | +$7.48M |
|
20
NewAmsterdam Pharma
NAMS
$2.71B
| $7.46M | 1.63% | 315,388 +50,000 | +19% | +$1.18M |
|
21
Ventyx Biosciences
VTYX
$171M
| $7.07M | 1.54% | 1,285,000 +145,000 | +13% | +$798K |
|
|
22
Intellia Therapeutics
NTLA
$1.22B
| $7.02M | 1.53% | 255,000 +156,000 | +158% | +$4.29M |
|
|
23
Compass Therapeutics
CMPX
$483M
| $6.28M | 1.37% | +3,170,000 | New | +$6.28M |
|
24
Xoma
XOMA
$392M
| $6.01M | 1.31% | 250,000 | – | – |
|
25
Liquidia Corp
LQDA
$2.38B
| $5.83M | 1.27% | 395,000 -50,000 | -11% | -$738K |
|